 Genocea Biosciences NASDAQ:GNCA had its target price cut by HC Wainwright from 32.00 to 9.00 in a research note released on Thursday morning, The Fly reports. They currently have a buy rating on the biotechnology companys stock. A number of other research firms have also weighed in on GNCA. Zacks Investment Research upgraded shares of ... 